| |
| |
|
| Insider
Information: |
Stahl Neil |
| Relationship: |
EVP Research and Devel... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
50,999 |
|
|
Indirect Shares
|
10,439 |
|
|
| Direct
Value |
$45,042,317 |
|
|
|
Indirect Value
|
$9,219,725 |
|
|
| Total
Shares |
61,438 |
|
|
| Total
Value |
$54,262,042 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
3
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
1.5
|
| Percentage
Gain/Loss : |
0.0%
|
 37.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regeneron Pharmaceuticals Inc |
REGN |
EVP Research and Devel... |
2024-02-26 |
50,999 |
2024-02-26 |
10,439 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2024-02-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,020 |
50,999 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2024-02-07 |
4 |
S |
$947.34 |
$7,637,954 |
D/D |
(8,037) |
52,019 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2024-02-02 |
4 |
D |
$956.65 |
$21,728,391 |
D/D |
(22,713) |
60,056 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2024-02-02 |
4 |
OE |
$399.66 |
$12,289,545 |
D/D |
30,750 |
82,769 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-12-11 |
4 |
D |
$844.09 |
$611,965 |
D/D |
(725) |
52,019 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
853 |
52,744 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-12-08 |
4 |
D |
$843.79 |
$682,626 |
D/D |
(809) |
51,891 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-11-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
400 |
52,700 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-08-22 |
4 |
S |
$840.53 |
$9,810,082 |
D/D |
(11,665) |
53,100 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-08-21 |
4 |
D |
$833.39 |
$31,948,006 |
D/D |
(38,335) |
64,765 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-08-21 |
4 |
OE |
$399.66 |
$19,983,000 |
D/D |
50,000 |
103,100 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,101 |
53,100 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-12-09 |
4 |
D |
$753.28 |
$351,028 |
D/D |
(466) |
51,999 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-11-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
330 |
52,465 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-08-05 |
4 |
S |
$606.78 |
$14,569,134 |
D/D |
(23,782) |
52,795 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-08-04 |
4 |
D |
$613.00 |
$43,656,634 |
D/D |
(71,218) |
76,577 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-08-04 |
4 |
OE |
$270.43 |
$25,690,850 |
D/D |
95,000 |
147,795 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-02-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
335 |
52,795 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-12-11 |
4 |
D |
$664.34 |
$500,248 |
D/D |
(753) |
53,130 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,926 |
53,883 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-12-03 |
4 |
D |
$632.45 |
$31,845,122 |
D/D |
(50,352) |
50,957 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-12-03 |
4 |
OE |
$179.13 |
$12,986,925 |
D/D |
72,500 |
101,309 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-11-29 |
4 |
GA |
$0.00 |
$0 |
I/I |
4,605 |
4,605 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-11-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,605 |
28,809 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-05-17 |
4 |
S |
$518.63 |
$9,101,460 |
D/D |
(17,521) |
24,280 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
